Souhaitez-vous accéder aux communiqués récents ?

Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and...

Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is...

Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with...

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million...

Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to...

Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer...

Der Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der EU...

Hausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses...

Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD...

Erste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern  Der Antrag auf Marktzulassung (MAA) basiert auf zwei...